The Protective Effects of *Helicobacter pylori* Infection on Allergic Asthma

Zhi Tong Zuo\(^a\)  Ya Ma\(^b\)  Yan Sun\(^a\)  Cui Qing Bai\(^a\)  Chun Hua Ling\(^c\)
Feng Lai Yuan\(^d\)

\(^a\)Department of Respiratory Disease, The Hospital Affiliated to Jiangnan University, Wuxi, China; \(^b\)Wuxi Medical College of Jiangnan University, Wuxi, China; \(^c\)Department of Respiratory Disease, First Affiliated Hospital of Soochow University, Suzhou, China; \(^d\)Department of Orthopaedics and Central Laboratory, The Hospital Affiliated to Jiangnan University, Wuxi, China

Keywords
*Helicobacter pylori* · Allergic asthma · Protective effect · Dendritic cells · Helper T cells · Regulatory T cells

Abstract
As an ancient Gram-negative bacterium, *Helicobacter pylori* has settled in human stomach. Eradicating *H. pylori* increases the morbidities of asthma and other allergic diseases. Therefore, *H. pylori* might play a protective role against asthma. The “disappearing microbiota” hypothesis suggests that the absence of certain types of the ancestral microbiota could change the development of immunology, metabolism, and cognitive ability in our early life, contributing to the development of some diseases. And the Hygiene Hypothesis links early environmental and microbial exposure to the prevalence of atopic allergies and asthma. Exposure to the environment and microbes can influence the growing immune system and protect subsequent immune-mediated diseases. *H. pylori* can inhibit allergic asthma by regulating the ratio of helper T cells 1/2 (Th1/Th2), Th17/regulatory T cells (Tregs), etc. *H. pylori* can also target dendritic cells to promote immune tolerance and enhance the protective effect on allergic asthma, and this effect relies on highly suppressed Tregs. The remote regulation of lung immune function by *H. pylori* is consistent with the gut-lung axis theory. Perhaps, *H. pylori* also protects against asthma by altering levels of stomach hormones, affecting the autonomic nervous system and lowering the expression of heat shock protein 70. Therapeutic products from *H. pylori* may be used to prevent and treat asthma. This paper reviews the possible protective influence of *H. pylori* on allergic asthma and the possible application of *H. pylori* in treating asthma.

Introduction
Since Gram-negative *Helicobacter pylori* was discovered, the relationship between *H. pylori* infection and asthma has gradually attracted people’s eyes. Kalach et al. [1] analyzed the infection of *H. pylori* in adults and chil-
H. pylori infection is decreasing in both adults and children in developed countries and several developing areas, which is opposite from the increased incidence of asthma in children and other allergic disorders. Ness-Jensen et al. [2] found that H. pylori infection has been related to a 40% decrease of asthma in those who are below the age of 18 years with abdominal obesity. A recent study found that 16.4% of children who were negative for H. pylori at the age of 2 and 10 had asthma at the age of 16, but if they were positive for H. pylori at the age of 12, they did not have asthma at the age of 16. It is suggested that the early exposure to H. pylori can prevent asthma [3]. Fouda et al. [4] used ELISA for determination of H. pylori IgG in the serum of asthma and healthy children. The results showed that the titer of IgG was negatively correlated with the degree of asthma. Serum H. pylori could prevent asthma in children and was inversely correlated with the severity of asthma. Accumulating evidence suggested that the infection of H. pylori, particularly CagA-positive H. pylori, was negatively correlated with the development of asthma. A study of Greek children has also proved this viewpoint [5]. Recent and earlier cross-sectional studies also suggested that H. pylori infection had protective effects on asthma [6–9]. However, not all studies supported this result, which still requires future research [10–16]. Although the effects of H. pylori in the pathophysiological mechanisms of asthma remain controversial, the researchers detected H. pylori exotoxin VacA in human lung biopsies and directly stimulated pulmonary airway epithelial cells to secrete inflammatory cytokines in vitro [17]. Moreover, H. pylori has been discovered in the lung tissues of patients with COPD [18]. More studies confirmed that the existence of H. pylori provided protective effects against asthma, and eradication of H. pylori may have a negative impact [19–21].

The immune system includes adaptive immunity (acquired immunity) and innate immunity (natural immunity) [22–24]. Adaptive immunity mainly recognizes “non-self” antigen and produces immune tolerance, and innate immunity is the first line of defense against pathogenic microorganism invasion, which can effectively distinguish self from pathogenic microorganism [25, 26]. The immune pathogenesis of allergic asthma is quite complex. The studies have focused on Toll-like receptors (TLRs), dendritic cells (DCs), helper T cells 1/2 (Th1/Th2), Th17, regulatory T cells (Tregs), etc. The formation of a complex interaction network between cells and receptors also provides a broad view for immunological research of asthma [27–29]. The followings are the possible protective mechanisms of H. pylori against allergic asthma reported in recent years and the possible associated treatment of asthma.

**Possible Protective Mechanisms of H. pylori against Allergic Asthma**

**The Hygiene Hypothesis**

The hygiene hypothesis [30, 31] links early environmental and microbial exposure to the prevalence of atopic allergies and asthma. The exposure to environment and microbes can help to form the growing immunity system and protect subsequent immune-mediated diseases [32]. “Unhygienic exposure” to microorganisms in an early age can prevent the development of allergic diseases in later years [33]. H. pylori infection usually occurs in children, and the way to be infected is related to unhygienic family environment or habits, and this association appears in mouse asthma models [34]. Early studies [35] have shown that the hygiene hypothesis may be related to Th1/Th2 imbalance. Synthetic adjuvants or microbial components can directly influence the cells in the innate immune system, including NK and DCs cells, and also stimulate the secretion of interferon-γ (IFN-γ), IL-12, and IFN-α, leading to the phenotypic transformation of allergen-specific Th2 to Th1 cells [7, 36]. The specific mechanisms still need to be further studied.

**Adjusting Th1/Th2 Balance**

It has been proved that Th1/Th2 ratio imbalance is one of the essential immunological mechanisms of asthma. According to the responses to foreign antigens, T cells can be divided into 2 types of effector cells, Th1 and Th2, which have totally different functions [37, 38]. Th1 mainly secretes IL-12, IFN-γ, and transforming growth factor β (TNF-β), activates macrophages and causes cytotoxicity, and mediates cellular immunity. Th2 mainly secretes IL-4, IL-5, and IL-13, activates B cells to produce immunoglobulin, and mediates humoral immunity. Th1 and Th2 are restrictive to each other and reach a balance. Asthma is a disease characterized by the count of Th2 and the effects it exerts [39–41].

H. pylori neutrophil-activating protein (HP-NAP) is one of the main virulence factors of H. pylori, which is also applied as a possible biomarker in the diagnosis of H. pylori-related diseases [42]. Studies [43–45] have shown that HP-NAP plays a protective role in asthma, which
could stimulate Th1 activation and attenuate Th2 response in allergy-related asthma both in vitro and in vivo (Fig. 1). In the research by Karakullukcu et al. [46], 18 cases (20.4%) of *H. pylori* DNA were discovered in 88 healthy stool samples but none in 92 asthmatic children (3–8 years). Multivariate Logistic regression analysis suggested that HP-NAP had a protective effect on asthma in male children. In order to verify HP-NAP as a regulatory factor against the Th2 inflammatory effect, Zhou et al. [47] exposed the mice to purified recombinant *H. pylori* NAP (rNAP) through intraperitoneal injection or inhalation. The increase and infiltration of the eosinophils were remarkably suppressed in the lungs of the asthma mice model induced by ovalbumin (OVA). Moreover, the count of eosinophils was decreased in the lavage fluid from bronchoalveolar (BALF) in the mice treated with rNAP. Additionally, the levels of IL-13 and IL-4 declined ($p < 0.01$), the levels of IFN-$\gamma$ and IL-10 elevated ($p < 0.01$), and the serum level of IgE declined ($p < 0.01$) in experimental groups in comparison with the control group. It is suggested that mucosal and systemic pretreatment of rNAP might attenuate asthma in the mice induced by OVA. Furthermore, rNAP could be used as a new method in preventing or treating allergic disorders. In phase I/II clinical trials, it has been reported that the effect of soluble IL-4 receptor (sIL-4R) was satisfactory in treating asthma. To discover more effective antiasthma therapies, Liu et al. [48] attempted to test whether the HP-NAP could increase the therapeutic effect of sIL-4R on asthma. In their research, pcDNA3.1-sIL-4R-NAP plasmid (PSN) was constructed, which could encode a fusion protein of murine HP-NAP and sIL-4R. PSN could remarkably reduce inflammation in the airway, suppress the secretion of OVA-specific IgE in serum, and reestablish the balance of Th1 and Th2. Moreover, PSN has been more effective in the treatment for asthma in comparison with the plasmid only generating sIL-4R.

**Adjusting Th17/Tregs Balance**

With the development of scientific research, Th1/Th2 imbalance cannot fully explain the mechanisms of asthma [49]. Although allergic asthma is often associated with abnormal TH2 cellular responses, a group of patients with severe disease showed a mixture of TH2 and TH17 cellular responses in the airways [50]. It was found that Th7 and Tregs cells were also significantly related to the pathogenesis of asthma [51–53]. Synergy of multiple pathways, such as Th2, Th17, and even eosinophil/neutrophil infiltration, has been found in some asthma models [54–56]. The view that eosinophilic asthma is an exclusive TH2 disorder and neutrophil asthma is an exclusive TH17 disorder may be oversimplified [57]. It has been found that the TH2 and TH17 inflammatory pathways regulate each other in asthma [58]. Th1/Th2 and Th7/Tregs and their various cytokines form an extremely complex interactive network [59, 60]. Th7 cells are defined as “proinflammatory” immune cells, which mainly secrete IL-17, mediate inflammatory responses, and pro-
mote neutrophil maturation, proliferation, and chemotaxis. Retinoid-related orphan receptor (ROR) gamma t (RORγt) is a key transcriptional factor in the differentiation of Th17 cells. The deletion of RORγt leads to the failure of Th17 differentiation [61, 62]. Tregs secrete IL-10 and other inhibitory cytokines. Tregs play an important role in maintaining immune balance. Tregs specifically express forkhead transcription factor p3 (Foxp3), suppress immune response, and mediate immune tolerance [63–65].

The protective mechanisms of *H. pylori* in inflammatory diseases such as asthma may be associated with induction of Tregs, which could highly suppress the immune activity [66–68]. Published data strongly suggested that *H. pylori* caused an increase in the response levels of Tregs, Th1, and Th17 in mouse models and human, which could prevent asthma. According to the ontogeny of the immune system, *H. pylori* tends to infect in one’s childhood and continues to stimulate immunity reaction throughout the life, including Th1, Th17, and Tregs responses. Additionally, children infected by *H. pylori* tend to have a stronger Tregs response than adults [69–72]. Once human is infected by *H. pylori*, Tregs are found to be highly active in the gastric mucosa. The secretion of IL-10 by Tregs in peripheral blood was significantly higher than that in *H pylori*-specific Th1 cells. When there was a strong Tregs reaction, the concentration of total IgE and allergen-specific IgE was low. Suppressing IL-10 could significantly restore the IgE reaction in animal models. Therefore, systematic IL-10 and Tregs may play a role in preventing allergies mediated by *H. pylori* [72].

Kyburz et al. [73] established C57BL/6 mice experimental models of house dust mite- or ovalbumin-induced airway inflammation and influenza A virus or *Citrobacter rodentium* infection. It was found that the exposure to *H. pylori* extract or its immunomodulator vacuolating cytotoxin in the perinatal stage could exert robust protective functions against allergic inflammation in the airway not only in the offspring of the first generation but also the second generation, which did not increase the susceptibility to bacterial or viral infection. The immune responses correlated with prevention of allergy include inhibiting the activities of effectors or T cells, expanding the subsets of regulatory T cells expressing RORγt, and FOXP3 demethylation. The diversity and composition of the microbiota in the gastrointestinal system are notably influenced by the perinatal exposure of *H. pylori*. In conclusion, *H. pylori* exposure not only works on the carriers but also on the next generations. Maternal nutrient, the exposure to microorganisms, tobacco, and other environmental factors influence the formation of the immune system in a fetus via an epigenetic way (Fig. 2).

**Inhibition of DCs**

DCs can devour and kill invasive microorganisms and present microbial antigens to T cells, thus participating in the innate immunity [25, 74]. DCs help the initial T cells polarize into Th2 effector cells or differentiate into Tregs [75, 76]. It has been suggested that *H. pylori* targets DCs to promote immune tolerance and enhance the protective effect against allergic asthma, and this effect relies on highly suppressed Tregs [77, 78]. Oertli et al. [79, 80] found the level of Foxp3, the main regulatory factor expressed by Tregs, was increased in immature T cells when *H. pylori* was exposed to DCs in cells and animal experiments. Depleting the DCs in *H. pylori*-infected mice in the neonatal stage resulted in the improvement of infection control and the destruction of specific tolerance to *H.
pylori. At the same time, it also aggravated the immune-pathological reactions driven by T cells. IL-18 secreted by DCs could directly act on T cells and promote transformation into Tregs. It promotes specific immune tolerance and asthma protection in mice. Vacuolating cytoxin A (VacA) and γ-glutamyl transpeptidase (GGT), 2 virulence factors in H. pylori, independently interfere with the maturation of DCs, thus promoting the tolerance of DCs. Shiu et al. [81] found that the infection of H. pylori can upregulate the expression of anti-inflammation factors including IL-1 receptor-associated kinase M (IRAK-M). The expression of IRAK-M activated by TLRs in DCs directly inhibited the inherent function of DCs, such as the upregulation of cytokines and costimulatory molecules, rather than affecting the response of Th17 and Tregs (Fig. 3).

Activation of TLRs

TLRs are a group of widely studied pattern recognition receptors, which are associated with the incidence and progression of asthma. At present, it is considered that TLRs are mainly expressed in the membrane or organelle capsule of antigen presenting cells (such as macrophages and DCs). TLRs participate in the early host defense and play an important role in the innate immune response. On the other hand, TLRs participate in the inflammatory response via secreting cytokines, chemokines, adhesion molecules, etc., and finally activate the acquired immune system. Different TLRs have different functions [82–84]. TLR2 is an important pattern recognition receptor in Tregs [85, 86] and TLR9 mainly plays a negative role in the regulation of allergic inflammation [87–89]. TLR4 not only relies on conserved sequences encoded by embryological genes to identify pathogenic microorganisms and activate innate immunity but also regulates adaptive immunity [90, 91]. In conclusion, TLRs are closely related to asthma [92].

In recent days, hypotheses were proposed that H. pylori could facilitate the activation of inflammasomes in mouse and human immune cells. The possible mechanisms and virulence factors stimulating the inflammasome have been discovered in animal and cell models. IL-1β could facilitate the responses of Th1 and Th17. IL-18 has been a hallmark in humans and mice infected by H. pylori, which plays an important role in H. pylori persistence, Tregs differentiation, and prevention of asthma. The secretion of IL-1β induced by H. pylori is regulated by the activation of NLRP3 (Nod-like receptor family member), caspase-1, and TLR2. The axis of TLR2/NLRP3/caspase-1/IL-18 was essential in the regulation of H. pylori-specific immune response which could prevent inflammatory bowel disease and asthma induced by allergens in mouse models [93–95].

NOD1 is considered as a pattern recognition receptor in cells and specifically targets the Gram-negative peptidoglycan, which plays an important role in host defense against infections (e.g., H. pylori and Shigella flexneri) [96]. The variations in the NOD1 gene contribute to inflammatory bowel disease and asthma. NOD1 could be activated by a rather low concentration of M-Tri DAP, which is a specific muropeptide ligand. Moreover, NOD1 could induce minimal secretion of IL-10, TNF-α, and IL-1β from...
Microorganisms in the gastrointestinal tract can reach the lower respiratory tract through gastroesophageal reflux [108]. Due to the increase in intestinal and alveolar capillary permeability in some patients, the bacteria from the intestinal mucosa can be transferred to the lungs through the blood circulation [109]. Changes in the pulmonary flora can also cause changes in the intestinal flora through the blood flow [110]. However, there is little evidence about direct shift of microorganisms between 2 sites [107].

Disorders of the gut can be observed in lung diseases [105, 111–114]. Influenza virus can change the composition of intestinal flora and cause intestinal immune damage through Th17 cell mediation [115]. Locally induced pulmonary anaphylaxis may also affect the composition of intestinal flora [116]. Studies have shown that the severity of intestinal symptoms is highly consistent with the severity of pulmonary symptoms [117, 118].

Intestinal microbes promote development of the body’s immune system early in life and affect the whole body and lungs through the blood and lymphatic system [104]. Both the gut and lungs have a strong mucosal defense system. For instance, intestinal and respiratory mucosal goblet cells can secrete IgA. The intestinal microflora can regulate pulmonary immune responses through bacterial lipopolysaccharide, short-chain fatty acids (SCFAs), and immune cells (e.g., Tregs and DCs), which can affect colonization of the lung microbiome [106, 119, 120]. The imbalance of intestinal flora is related to a variety of lung diseases such as asthma. The adjustment of intestinal flora can alleviate the symptoms and reduce the incidence of asthma. Probiotics supplementation has a certain preventive and therapeutic effect on asthma in mice. High-fiber diet can change the intestinal flora of mice and increase the content of SCFAs, thus inhibiting the activity of Th2 cells [121]. H. pylori can cause chronic immunopathologic changes in the stomach and dysbacteriosis and promote regulation of the immune function of the lung. H. pylori protects asthma by DCs, Tregs, etc., which is consistent with the gut-lung axis theory [106, 110, 122] (Fig. 4).

Reducing the Expression of Heat Shock Protein 70
Heat shock protein 70 (HSP70), an ATP-dependent chaperone protein, is a known inhibitor of caspase activation, showing antiapoptotic activity in a variety of cells [123, 124]. It has been found that HSP70 might play a role in promoting asthma inflammation. HSP70 deficiency leads to significant reduction in airway inflammation, goblet cell proliferation, and Th2 cytokine production, including IL-4, IL-5, and IL-13, and targeting HSP70 can...
alleviate the potential utility of allergen-induced Th2 cytokines, goblet cell proliferation, and airway inflammation [125–127]. HSP70/CD80 DNA vaccine can inhibit airway remodeling by regulating the development of Th1/Th2 subsets in asthma mice, and HSP70 may be a potential target for inhaled glucocorticoids (ICS) in the treatment of asthma [128, 129]. Another study also found that HSP70 directly inhibited irritation-induced gastric ulcer formation and promoted gastric ulcer healing [130]. HSP70 can also protect the gastric mucosa through inhibition of apoptosis, proinflammatory cytokines, and cell adhesion molecules [131, 132]. *H. pylori* infection alters gastric epithelial cell proliferation and reduces or even abolishes HSP70 gene expression [133, 134]. The possible mechanisms included inducing the cellular protective effect of HSP70 against *H. pylori* infection via inhibiting the expression of inducible nitric oxide synthase (iNOS). However, the reliability and accuracy, as well as the underlying mechanisms, in this relationship remains poorly understood, and large-sample clinical research must be performed to verify this theory [135, 136]. The direct mechanism of HSP70 related *H. pylori* in protecting asthma remains to be further explored.

The “Disappearing Microbiota” Hypothesis

*H. pylori* is a kind of ancient, dominant bacteria that settle in the human stomach and closely attach to host cells. *H. pylori* might be a regular member in the gastric microflora in human. With the improvement of environment and lifestyle, and the eradication of *H. pylori*, the prevalence of *H. pylori* infection in the developed countries has declined sharply, while the incidence of asthma, obesity, and allergic diseases has increased rapidly [137–139]. According to Blazer [140], the proponent of the “disappearing microbiota” hypothesis, the absence of certain bacterial species from the ancestral microbiota could
change the environment where cognitive, metabolic, and immunological functions develop in our early life. This change could result in the increased susceptibility to some diseases. The disappearance of ancient microbiota may be a universal paradigm leading to modern diseases. This harmful trend implies that we need to put efforts in understanding and reversing the reasons contributing to the disappearing microbiota [5].

**Treatment of Asthma Related to *H. pylori* Infection**

Eradicating *H. pylori* could decrease the occurrence of dyspepsia, peptic ulcer, and gastric malignancy. However, concerns of extensive application of eradication treatment are also raised, such as the resistance to antimicrobial agents and an increase in the prevalence of disorders that are negatively correlated with the infection of *H. pylori*, including obesity, asthma, GERD, and Barrett esophagus [141, 142]. Eradicating the infection of *H. pylori* is considered as a double-edged sword. Thus, selective identification and elimination of only the virulent strains of *H. pylori* are of great importance in the eradication therapy [143]. Epidemiology studies and experiments have demonstrated that exposure to *H. pylori* could prevent asthma, especially in one’s childhood. Recently, in vivo studies have shown that live bacteria are not involved in induction of this protective role. Administering an extract of *H. pylori* in a newborn could prevent inflammation in the airway and metaplasia of the goblet cells. Injection of *H. pylori* extract could inhibit DCs in processing the allergen in the mediastinal lymph nodes and lungs. These results suggest that the extract of *H. pylori* following sensitization could effectively prevent allergic airway disorders [144]. *H. pylori* targets DCs and relies on highly suppressed Tregs. Since HP-NAP is considered as a possible regulator for Tregs and can inhibit allergic inflammation of asthma, it is possible to develop HP-NAP as an efficient *H. pylori*-specific vaccine to treat allergic asthma [78, 145, 146]. van Wijck et al. [147] have shown that *H. pylori* extract can effectively reduce the production of mucus and multiple characteristics of inflammation in the mice rechallenged by house dust mite. VacA and GGT, 2 persistence determinants in *H. pylori*, are sufficient in preventing asthma and could be given in their purified forms for treatment [148]. Transmaternal *H. pylori* exposure can reduce allergic airway inflammation in the offspring through Tregs and also provide new insights for interventional therapy of asthma [73]. High doses of vitamin D and fish oil supplements during pregnancy have been shown to help prevent and control disease in the offspring [149], and maternal treatment of Zika virus infection with the IL-1 receptor antagonist can directly reduce fetal neuroinflammatory response through placental immunity [150]. Immunological methods can be used to design vaccines against *H. pylori* infection, and it should also be used for the prevention of asthma across generations [64, 68, 70]. VacA, GGT, HP-NAP, Tregs, and even FOXP3 each play an important role in *H. pylori*-related asthma protection. It would be a very interesting topic if we could design an effective monoepitope or multiepitope vaccine that could be used by the mother before pregnancy, during pregnancy, or during breastfeeding to prevent asthma of the offspring through the placenta or breast milk.

**Conclusion**

*H. pylori* may protect allergic asthma by regulating Th1/Th2 and Th17/Tregs balance, inhibiting DCs and HSP70, activating TLRs, and reducing gastroesophageal reflux. The hygiene hypothesis, the “disappearing microbiota” hypothesis, and the gut-lung axis theory all support this protective effect. Therapeutic products made by *H. pylori* may be used to prevent and treat asthma. In particular, perinatal exposure to *H. pylori* can reduce allergic airway inflammation in the offspring, which also provide a new insight for interventional treatment of asthma.

**Acknowledgement**

The authors acknowledge the editorial assistance of Shanghai Xu Mu Biotechnology Co., Ltd., and Miss. Xia Li for the illustrations.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

The authors did not receive any funding.

**Author Contributions**

Z.Z. and F.Y. conceived and designed this study and contributed equally to this work. Y.M., Y.S., C.B., and C.L. participated actively in the study and approved the submitted manuscript.
Helicobacter pylori and Allergic Asthma

References

1. Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter. 2017;22(Suppl 1):e12144.

2. Ness-Jensen E, Langhammer A, Hveem K, Lu Y. Helicobacter pylori in relation to asthma and allergy modified by abdominal obesity: the HUNT study in Norway. World Allergy Organ J. 2019;12(5):100035.

3. Melby KK, Carlens KL, Håland G, Samdal HH, Carlens KH. Helicobacter pylori in early childhood and asthma in adolescence. BMC Res Notes. 2020;13(1):79.

4. Fouda EM, Kamel TB, Nabih ES, Abdelazem AA. Helicobacter pylori seropositivity protects against childhood asthma and inversely correlates to its clinical and functional severity. Allergol Immunopathol. 2018;46(1):76–81.

5. Tsigalou C, Konstantinidis TG, Cassimos D, Kato H, Pattison R, Bhandari S. Inverse relationship between Helicobacter pylori infection and childhood asthma in Greece: a case-control study. Germs. 2019;9(4):182–7.

6. Kato H, Pattison R, Bhandari S. Inverse relationship between Helicobacter pylori infection and asthma in US adults with peptic ulcer disease. Indian J Gastroenterol. 2017;36(2):158–9.

7. Chen C, Xun P, Tsinovoi C, He K. Accumulated evidence on Helicobacter pylori infection and the risk of asthma: a meta-analysis. Ann Allergy Asthma Immunol. 2017;119(2):137–45.e2.

8. Lim JH, Kim N, Lim SH, Kwon JW, Shin CM, Chang YS, et al. Inverse relationship between Helicobacter pylori infection and asthma among adults younger than 40 years: a cross-sectional study. Medicine. 2016;95(8):e2609.

9. Iizasa H, Ishihara S, Richardo T, Kanehiro Y, Yoshihaya H. Dysbiotic infection in the stomach. World J Gastroenterol. 2015;21(40):11450–7.

10. Wang YC, Lin TY, Shang ST, Chen HJ, Kao HH, Carlsen KH. Helicobacter pylori in early childhood and asthma and allergy modified by abdominal obesity: a nationwide cohort study. Eur J Clin Microbiol Infect Dis. 2017;36(9):1587–94.

11. Molina-Infante J, Gutierrez-Junguera C, Sarvarino E, Penagini R, Modolli I, Bartolo O, et al. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. Am J Gastroenterol. 2018;113(7):972–9.

12. Höfle T, Vila AM, Caudri D, den Hoed CM, Perez-Perez GI, Blaser MJ, et al. The impact of Helicobacter pylori on atopnic disorders in childhood. Helicobacter. 2012;17(3):232–7.

13. Wang Q, Yu C, Sun Y. The association between asthma and Helicobacter pylori: a meta-analysis. Helicobacter. 2013;18(1):41–53.

14. Wang Y, Bi Y, Zhang L, Wang C. Is Helicobacter pylori infection associated with asthma risk? A meta-analysis based on 770 cases and 785 controls. Int J Med Sci. 2012;9(7):603–10.

15. Chang SS, Hu HY. No inverse relationship between Helicobacter pylori infection and adult peptic ulcer disease. Hepatogastroenterology. 2014;61(130):529–34.

16. Sabbagh P, Javanian M, Koppolu V, Vagisala VR, Ebrahimpour S. Helicobacter pylori infection in children: an overview of diagnostic methods. Eur J Clin Microbiol Infect Dis. 2019;38(6):1035–45.

17. Nakashima S, Kagawa T, Yura H, Tomonaga M, Harada T, Hara A, et al. Identification of Helicobacter pylori VacA in human lung and its effects on lung cells. Biochem Biophys Res Commun. 2015;460(3):721–6.

18. Huang YJ, Kim E, Cox MJ, Brodie EL, Brown R, Wiener-Kronish JP, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS. 2010;14(1):9–59.

19. Karimi A, Fakhkhi-Derakhshan K, Imanzadeh F, Rezaei M, Cavasozhade Z, Maham S. Helicobacter pylori infection and pediatric asthma. Iran J Microbiol. 2013;5(2):132–5.

20. Taye B, Enquasellase F, Tsegaye A, Amberbir A, Medhin G, Fogarty A, et al. Association between infection with Helicobacter pylori and atopy in young Ethiopian children: a longitudinal study. Clin Exp Allergy. 2017;47(10):1299–308.

21. Popescu D, Andronescu D, Babes PA. The association between Helicobacter pylori infection and liver and biliary tract disorders. Curr Pharmaceut Anal. 2017;4(2):137–45.

22. Hossain FMA, Choi JY, Uyanga E, Park SO, Eo SK. The interplay between host immunity and respiratory viral infection in asthma exacerbation. Immune Netw. 2019;19(5):e31.

23. Eisenbarth SC, Cassel S, Bottomly K. Understanding of the hygiene hypothesis through Helicobacter pylori neutrophil-activating protein. 2017;45(2):160–8.

24. Lin CL, Hsiao G, Wang CC, Lee YL. Imperatorin exerts antiallergic effects in Th2-mediated allergic asthma via induction of IL-10-producing regulatory T cells by modulating the function of dendritic cells. Pharmacol Res. 2016;110:111–21.

25. Abdelaziz MH, Abdelwahab SF, Wan J, Cai W, Huixuan W, Jianjun C, et al. Alternatively activated macrophages: a double-edged sword in allergic asthma. J Transl Med. 2020;18(1):58.

26. Puggioni F, Alves-Correia M, Mohamed MF, Stomeo N, Mager R, Marinoni M, et al. Immunostimulants in respiratory diseases: focus on Pidotimod. Multidiscip Respir Med. 2019;14:31.

27. Ege MJ. The hygiene hypothesis in the age of the microbiome. Ann Am Thorac Soc. 2017;14(Suppl 5):S348–53.

28. Palomares O, Yaman G, Akkoc T, Akkos C, Akdls M, Akdls CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010;40(5):1232–40.

29. Daschner AR, Gonzalez Fernandez A. Allergy in an evolutionary framework. J Mol Evol. 2020;80(1):66–76.

30. Asayama K, Kobayashi T, D’Alessandro-Gabazza CN, Toda M, Yasuma T, Fujimoto H, et al. Protein S protects against allergic bronchial asthma by modulating Th1/Th2 balance. Allergy. 2020;75(9):2267–78. https://sci-hub. se/10.1111/all.14261.

31. Hwang YH, Kim SJ, Yee ST. Phthalate-ma- tured dendritic cells induce the differentiation of Th1 cells. Int J Mol Sci. 2020;21(5):1753.

32. Hsu C, Li Z, Feng J, Tang Y, Qin L, Hu X, et al. Glucocorticoids modulate Th1 and Th2 responses in asthmatic mouse models by inhibition of notchi signaling. Int Arch Allergy Immunol. 2018;185(1–2):44–52.

33. Chen Z, Liu N, Xiao J, Wang Y, Dong R. The amygdala via the paraventricular nucleus regulates asthma attack in rats. CNS Neurosci Ther. 2020;26(7):730–40.

34. Hwang YH, Paik MJ, Yee ST. Disonoyln phthalate induces asthma via modulation of Th1/Th2 equilibrium. Toxicol Lett. 2017;272:49–59.

35. Hong ZW, Yang YC, Pan T, Tzeng HF, Fu HW. Differential effects of DEAE negative mode chromatography and gel-filtration chromatography on the charge status of Helicobacter pylori neutrophil-activating protein. PLoS One. 2017;12(3):e0173632.
43 Amedei A, Codozo G, Del Prete G, de Bernard M, D’Elissio MM. The effect of Helicobacter pylori on asthma and allergy. J Asthma Allergy. 2010; 3:139–47.
44 D’Elissio MM, Codozo A, Amedei M, Mazzu P, Berton G, Zanotti G, et al. Helicobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol. 2009;56(1):1–8.
45 Konturek PC, Riencke HA, Hahn EG, Raithel M. Helicobacter pylori as a protective factor against food allergy. Med Sci Monit. 2008; 14(9):CR452–8.
46 Karakullukçu A, Tokman HB, Nepesov S, Demirci M, Sarıbas S, Vehid S, et al. The protective role of Helicobacter pylori neutrophil-activating protein in childhood asthma. Allergol Immunopathol. 2017;45(6):521–7.
47 Zhou S, Huang Y, Liang B, Dong H, Yao S, Chen Y, et al. Systemic and mucosal pre-administration of recombinant Helicobacter pylori HINH, a neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice. FEMS Microbiol Lett. 2017;364(2):fnw288.
48 Liu X, Fu G, Ji Z, Huang X, Ding C, Jiang H, et al. A recombinant DNA plasmid encoding the sIL-4R-NAP fusion protein suppresses airway inflammation in an OVA-induced mouse model of asthma. Inflammation. 2016;39(4):1434–40.
49 Zhao Y, Yang J, Gao YD, Guo W. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol. 2010;151(4):297–307.
50 Massoud AH, Charbonnier LM, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to Th17-like cells. Nat Med. 2016;22(9):1013–22.
51 Wang ZE, Zhou XY, Yang Y, Liu ZY. [Effect of Jian’erle granule on Thl7/Treg imbalance of asthma mice]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016;36(12):1510–4.
52 Zhu J, Yamane H, Paul WE. Determination of the clinical outcome of Helicobacter pylori infection. Microb Pathog. 2019;24(Suppl 1):e12644.
53 Peng J, Li XM, Zhang GR, Cheng Y, Chen X, et al. Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. Cytokine. 2020;126:154866.
54 Peng J, Li XM, Zhang GR, Cheng Y, Chen X, et al. Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. Cytokine. 2020;126:154866.
55 Li T, Gonzalez J, Pinchuk I, Beswick E, Reyes V. Helicobacter pylori elicits B7H3 expression on gastric epithelial cells: implications in local T cell regulation and subset development during infection. Clin Oncol Res. 2019;2(5):2–12.
56 Nakamura T, Kusama S, Ito M, Ito T, et al. Helicobacter pylori infection and extragastric diseases. Curr Top Microbiol Immunol. 2017;400:325–47.
57 Jafarzadeh A, Larussa T, Nematí M, Jalalpour S. T cell subset plays an important role in the determination of the clinical outcome of Helicobacter pylori infection. Microbiol Pathog. 2018;116:227–36.
58 Lehouris P, Feoktisto RL. Review: helicobacter: inflammation, immunology, and vaccines. Helicobacter. 2019;24(Suppl 1):e12644.
59 Li HT, Lin YS, Ye QM, Yang XN, Zou XL, Yang HL, et al. Airway inflammation and remodelling of cigarette smoking exposure ovalbumin-induced asthma is alleviated by Cpg oligodeoxynucleotides via affecting dendritic cell-mediated Th17 polarization. Int Immunopharmacol. 2020;82:106361.
60 Nadeem A, Ahmad SF, Al-Harbi NO, Ibrahim HE, Siddiqui N, Al-Harbi MM, et al. Inhibition of Bruton’s tyrosine kinase and IL-2 induction of T-cell killer suppresses both neutrophilic and eosinophilic airway inflammation in an ockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy. PharmacoRes. 2019;148:104441.
61 Santana FPR, da Silva RC, Grecco SD, Pinheiro AJMCR, Caperuto LC, Arantes-Costa FM, et al. Inhibition of MAPK and STAT3-phosphorylation in dendritic cells at the origin of asthma. Immunobiology. 2019;135:3566.
62 Cui H, Huang J, Lu M, Zhang Q, Qin W, Zhao Y, et al. Antagonistic effect of vitamin E on nAl2O3-induced exacerbation of Th2 and Th17-mediated allergic asthma via oxidative stress. Environ Pollut. 2019;252(2P B):1519–31.
63 Kardan M, Rafiei A, Ghaffari J, Valadan R, Morsalzahan J, Haj-Ghorbani ST. Effect of ginger extract on expression of GATA3, T-bet and ROR-γt in peripheral blood mononuclear cells of patients with allergic asthma. Allergol Immunopathol. 2019;47(4):378–85.
64 Nemattalab M, Senagari M, Tahter M, Mahjoob M, Nazari Chamaki F, Mojtahedi A, et al. Transmammary Helicobacter pylori-specific immune tolerance, and drives Treg differentiation, murine Helicobacter pylori infection reduces alergic airway inflammation in offspring through regulatory T cells. J Allergy Clin Immunol. 2019;143(4):e1496–e11.
65 Lambrecht BN, Hammad H. Biology of lung dendritic cells at the origin of asthma. Immunity. 2009;31(3):412–24.
66 Lee DCP, Nay QN, Thian M, Prabhu N, Furuhashi K, Kemeny DM. Prior exposure to inhaled allergen enhances anti-viral immunity and T cell priming by dendritic cells. PLoS One. 2018;13(1):e0190063.
67 Ammon L, Lehmann CHK, Baranska A, Schoen J, Heger L, Dudziak D. Transcriptional control of dendritic cell development and functions. Int Rev Cell Mol Biol. 2019;349:55–151.
68 Oertli M, Müller A. Helicobacter pylori targets dendritic cells to induce immune tolerance, promote persistence and confer protection against allergic asthma. Gut Microbes. 2012;3(6):566–71.
69 Arnold IC, Hitzler M, Müller A. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol. 2012;2:10.
70 Oertli M, Sundquist M, Hitzler I, Engel DB, Arnold IC, Reuter S, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest. 2012;122(3):1082–96.
71 Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, et al. Helicobacter pylori y-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA. 2013;110(8):3047–52.
72 Shiu J, Czinn SJ, Kobayashi KS, Sun Y, Blanchard TG. IRAK-M expression limits dendritic cell activation and proinflammatory cytokine production in response to Helicobacter pylori. PLoS One. 2013;8(6):e66914.
Helicobacter pylori and Allergic Asthma

82 Farroksi S, Abbasarid N, Movahed A, Khazaee HA, Pishjoo M, Rezaei N. TLR9-based immunotherapy for the treatment of allergic diseases. Immunotherapy. 2017;9(4):339–46.

83 Månsson Kvarnhammar A, Tengroth L, Adner M, Cardell LO. Innate immune receptors in human airway smooth muscle cells: activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 agonists. PLoS One. 2013;8(7):e68701.

84 Lucas K, Maes M. Role of the Toll-like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013;48(1):190–204.

85 George JA, Park SO, Choi JY, Uyanga E, Eo SK. Double-faced implication of CD4(+)/Foxp3(+) regulatory T cells expanded by acute dengue infection via TLR2/MyD88 pathway. Eur J Immunol. 2020;50(7):1000–18.

86 Nawijn MC, Motta AC, Gras R, Shirinbak S, Lucas K, Maes M. Role of the Toll like receptor (TLR) in ricin toxin-induced inflammatory bowel disease. Curr Top Microbiol Immunol. 2019;421:267–302.

87 Ying L, Ferrero RL. Role of NOD1 and ALPK1/TIF1A signalling in innate immunity against Helicobacter pylori infection. Curr Top Microbiol Immunol. 2019;421:159–77.

88 van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BM, Mengin-Lecreulx D, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol. 2005;35(8):2471–6.

89 Ng MT, Van’t Hof R, Crockett JC, Hope ME, Berry S, Thomson J, et al. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9-1227T/C polymorphism is associated with Helicobacter pylori infection. Infect Immun. 2010;78(3):1345–52.

90 Della Pena-Ponce MG, Jimenez MT, Hansen LM, Solnick JV, Miller LA. The Helicobacter pylori type IV secretion system promotes IL-8 synthesis in a model of pediatric airway epithelium via p38 MAP kinase. PLoS One. 2017;12(8):e0183324.

91 Kumar P, Singh G, Goyal JP, Khera D, Singh SK. Double-faced implication of CD4(+) T cells in asthma: the gut(-)lung axis. Int Arch Allergy Immunol. 2021;182:53–64.

92 Gupta N, Kumar R, Agrawal B. New players in immunity to tuberculosis: the host microbiome, lung epithelium, and innate immune cells. Front Immunol. 2020;9:709.

93 Wang J, Li F, Wei H, Lian ZX, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med. 2014;211(12):2397–410.

94 Vital M, Harkema JR, Rizzo M, Tiedje J, Brandenberger C. Alterations of the murine gut microbiome with age and allergic airway disease. J Immunol Res. 2015;2015:892568.

95 Pachathundikandi SK, Blaser N, Backert S. Mechanisms of inflammasome signaling, microRNA induction and resolution of inflammation by Helicobacter pylori. Curr Top Microbiol Immunol. 2019;421:267–302.

96 Pachathundikandi SK, Blaser N, Backert S. Mechanisms of inflammasome signaling, microRNA induction and resolution of inflammation by Helicobacter pylori. Curr Top Microbiol Immunol. 2019;421:267–302.

97 van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BM, Mengin-Lecreulx D, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol. 2005;35(8):2471–6.

98 Ng MT, Van’t Hof R, Crockett JC, Hope ME, Berry S, Thomson J, et al. Increase in NF-

kappaB binding affinity of the variant C allele of the toll-like receptor 9-1227T/C polymorphism is associated with Helicobacter pylori infection. Infect Immun. 2010;78(3):1345–52.

99 Della Pena-Ponce MG, Jimenez MT, Hansen LM, Solnick JV, Miller LA. The Helicobacter pylori type IV secretion system promotes IL-8 synthesis in a model of pediatric airway epithelium via p38 MAP kinase. PLoS One. 2017;12(8):e0183324.

100 Kumar P, Singh G, Goyal JP, Khera D, Singh SK. Double-faced implication of CD4(+) T cells in asthma: the gut(-)lung axis. Int Arch Allergy Immunol. 2021;182:53–64.

101 He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut-lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol. 2017;43(1):81–95.

102 Anand S, Mande SS. Diet, microbiota and gut-lung connection. Front Microbiol. 2018;9:2147.

103 Frati F, Salvatori C, Incorvaia C, Bellucci A, Di Cara G, Marcucci F, et al. The role of the microbiome in asthma: the gut(-)lung axis. Int J Mol Sci. 2018;20(1):123.

104 Bassis CM, Erb-Downward JR, Dickson RP, et al. Human metapneumovirus impairs apoptosis of nasal epithelial cells in asthma via HSP70. J Innate Immun. 2017;9(1):52–64.

105 Koch KN, Hartung ML, Urban S, Kyburz A, Finn J, et al. Helicobacter ure-ase-induced activation of the TLR4-TRIF pathway can protect against the acetaminophen-induced liver injury. Hepatol. 2017;65(1):2147.

106 Bennis K, de Galan M, Guex-Marin AM, Le Moal M, Del Rio-Chivardi J, Muriel-Vizier C, et al. The human gut microbiome and respiratory disease. FEBS Lett. 2016;590(21):3721–38.

107 Koch KN, Hartung ML, Urban S, Kyburz A, Finn J, et al. Helicobacter ure-ase-induced activation of the TLR4-TRIF pathway can protect against the acetaminophen-induced liver injury. Hepatol. 2017;65(1):2147.

108 Koch KN, Hartung ML, Urban S, Kyburz A, Finn J, et al. Helicobacter ure-ase-induced activation of the TLR4-TRIF pathway can protect against the acetaminophen-induced liver injury. Hepatol. 2017;65(1):2147.
124 Liu L, Huang Y, Feng X, Chen J, Duan Y. Overexpressed Hsp70 alleviated formaldehyde-induced apoptosis partly via PI3K/Akt signaling pathway in human bronchial epithelial cells. *Environ Toxicol.* 2019;34(4): 495–504.

125 Harkins MS, Moseley PL, Iwamoto GK. Regulation of CD23 in the chronic inflammatory response in asthma: a role for interferon-gamma and heat shock protein 70 in the TH2 environment. *Ann Allergy Asthma Immunol.* 2003;91(6):567–74.

126 Yombo DK, Mentink-Kane MM, Wilson MS, Wynn TA, Madala SK. Heat shock protein 70 is a positive regulator of airway inflammation and goblet cell hyperplasia in a mouse model of allergic airway inflammation. *J Biol Chem.* 2019;294(41):15082–94.

127 Huang X, Tan X, Liang Y, Hou C, Qu D, Li M, et al. Differential DAP7L release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients. *Sci Rep.* 2019;9(1):19241.

128 Yan L, Xiao-Ling S, Zheng-Yan C, Guo-Ping L, Sen Z, Zhuang C. HSP70/CD80 DNA vaccine inhibits airway remodeling by regulating the transcription factors T-bet and GATA-3 in a murine model of chronic asthma. *Arch Med Sci.* 2013;9(5):906–15.

129 Jiang H, Zhang X, Chi X, Wang J, Wang J, Dou J. [The effect of inhaled glucocorticoid therapy on serum proteomics of asthmatic patients]. Zhonghua Jie He He Hu Xi Za Zhi. 2014;37(4):274–8.

130 Saremi K, Rad SK, Khalilzadeh M, Hussaini J, Majid NA. In vivo acute toxicity and anti-gastric evaluation of a novel dichloro Schiff base: Bax and HSP70 alteration. *Acta Biochim Biophys Sin.* 2020;52(1):26–37.

131 deFoneska A, Kaunitz JD. Gastrointestinal mucosal defense. *Curr Opin Gastroenterol.* 2010;26(6):604–10.

132 Sidahmed HM, Azizan AH, Mohan S, Abdulla MA, Abdelwahab SI, Taha MM, et al. Gastroprotective effect of desmosdumotin C isolated from Mitrella kentii against ethanoll-induced gastric mucosal hemorrhage in rats: possible involvement of glutathione, heat-shock protein-70, sulphydryl compounds, nitric oxide, and anti-Helicobacter pylori activity. *BMC Complement Altern Med.* 2013;13:183.

133 Tao L, Zou H, Huang Z. Effects of Helicobacter pylori and heat shock protein 70 on the proliferation of human gastric epithelial cells. *Gastroenterol Res Pract.* 2014;2014:794342.

134 Pierzchalski P, Krawiec A, Ptak-Belowska A, Baranska A, Konturek SJ, Pawlik WW. The mechanism of heat-shock protein 70 gene expression abolation in gastric epithelium caused by Helicobacter pylori infection. *Helicobacter.* 2006;11(2):96–104.

135 Qu B, Jia Y, Liu Y, Wang H, Ren G, Wang H. The detection and role of heat shock protein 70 in various nondisease conditions and disease conditions: a literature review. *Cell Stress Chaperones.* 2015;20(6):885–92.

136 Targosz A, Pierzchalski P, Krawiec A, Szczuky U, Brozowski T, Konturek SJ, et al. Helicobacter pylori inhibits expression of heat shock protein 70 (HSP70) in human epithelial cell line. Importance of Cag A protein. *J Physiol Pharmacol.* 2006;57(2):265–78.

137 Taube C, Muller A. The role of Helicobacter pylori infection in the development of allergic asthma. *Expert Rev Respir Med.* 2012;6(4):441–9.

138 Otero LL, Ruiz VE, Perez Perez GI. Helicobacter pylori ameliorates parameters of airway inflammation and goblet cell hyperplasia following repeated allergen exposure. *Int Arch Allergy Immunol.* 2019;180(1):1–9.

139 Engler DB, Reuter S, van Wijck Y, Urban S, Kyburz A, Maxeiner J, et al. Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. *Proc Natl Acad Sci U S A.* 2014;111(32):11810–5.

140 Bisgaard H, Vissing NH, Carson CG, Bischoff AL, Folsgaard NV, Kreiner-Moller E, et al. Deep phenotyping of the unselected Copenhagen Allergy COPSAC2010 birth cohort study. *Clin Exp Allergy.* 2013;43(12):1384–94.

141 Lei J, Vermillion MS, Jia B, Xie H, Xie L, McLane MW, et al. IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection. *JCI Insight.* 2019;4(7):e122678.